AndroFeme® 1

A New Era in Women’s Health in New Zealand

Introducing AndroFeme® 1

A New Era in Women’s Health in New Zealand

AndroFeme® 1, a testosterone therapy developed specifically for postmenopausal women, is now registered in New Zealand. This marks a significant milestone for women’s health, providing the first licensed treatment in the country indicated for Hypoactive Sexual Desire Dysfunction (HSDD), a condition that affects 1 in 3 women aged 40–64¹,²,³.

AndroFeme® 1 is a non-funded, prescription-only medicine. Locally registered stock is anticipated to be available in Q3 2025.

DATA SHEET

WHAT IS HSDD?

HSDD is the most common form of sexual dysfunction in women4, defined by persistent and distressing low sexual desire. It can impact emotional well-being, relationships, and overall quality of life.

Why AndroFeme® 1?

Administered via a user-friendly applicator, AndroFeme® 1 delivers low, controlled doses of testosterone to help restore levels to those typical before menopause.

Specifically formulated for women.

Clinically proven to be effective with a known tolerability.

Non-funded, prescription-only therapy-normal doctors' fees and a prescription fee will apply.

Topical cream applied to the skin for consistent dosing.

Works with or without menopausal hormone therapy.

Improvement typically seen within 4–8 weeks.

Consumer Medicine Information

Next Steps

Women interested in treatment should speak with a menopause-informed GP or specialist to determine if this treatment may be right for them. Blood tests are recommended prior to treatment to guide and inform personalised dosing.

Brought to New Zealand by Alchemy Health
Partnering with Lawley Pharmaceuticals, a trusted Australian developer of body-identical hormone therapies.

AndroFeme® 1 is a non-funded prescription medicine containing 1% w/v testosterone (10mg testosterone per 1 mL). Normal doctors’ fees and a prescription charge will apply. AndroFeme® 1 is indicated for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women. AndroFeme® 1 has risks and benefits. Testosterone supplementation in women must be monitored closely, especially at onset of treatment. Ask your doctor if AndroFeme® 1 is right for you. Use only as directed. If symptoms continue or side effects develop, see your doctor, pharmacist or healthcare professional. For further information about AndroFeme® 1, see the Consumer Medicine Information (CMI) available at www.medsafe.govt.nz Alchemy Health NZ Ltd, Auckland. TAPS NP22596

References: 1. Simon JA Climacteric 2018; 5:415–427 2. Worsley R. J Sex Med. 2017 May; 14(5):675–686 3. Fooladi E. Climacteric 2014; 17:674–681 4. Goldstein I, Mayo Clin Proc 2017;92(1):114–128